CLINICAL RESEARCH STUDY
SUNFLOWER Study
A Clinical Trial for Women with Non-Atypical Endometrial Hyperplasia (NAEH)
We are conducting a Phase 3 clinical research study evaluating whether the hormonal intrauterine system Mirena can effectively treat non-atypical endometrial hyperplasia — a thickening of the uterine lining without precancerous changes.
This study compares Mirena to oral Medroxyprogesterone acetate, a commonly used hormonal treatment.
Study overview
PURPOSE
To determine whether Mirena can return the uterine lining to normal after 6 months of treatment.
TOTAL PARTICIPATION TIME
Up to 10 months
STUDY DESIGN
- Phase 3, randomized, open-label study
- 2 treatment groups — Mirena or oral medroxyprogesterone acetate
- 6 months of treatment + 3 months of follow-up
Visits approximately every 3 months
Who may qualify
- Age 18 or older
- Abnormal bleeding or diagnosis of Non-Atypical Endometrial Hyperplasia
- Willing to receive either an intrauterine system or oral hormone therapy
- Meet additional study health criteria
Both premenopausal and postmenopausal women may qualify.
Why Participate
- Close medical monitoring at no cost
- Regular ultrasounds and biopsy evaluations
- Contribution to research that may expand treatment options for women
COMPENSATION
Up to $1,600
For time and travel